Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.
Ajai Chari, MD, a professor of medicine, a hematologist, and an oncologist at Mount Sinai Hospital, discusses the approval of belantamab mafodotin-blmf (Blenrep) in relapsed/refractory multiple myeloma.
Belantamab mafodotin in an antibody-drug conjugate (ADC) that is composed of a toxin attached to a cytotoxic payload, says Chari. Moreover, the agent targets BCMA, and the conjugate is monomethyl auristatin F.
Notably, the agent was FDA approved on August 5, 2020 for the treatment of adult patients with relapsed/refractory multiple myeloma who have received 4 prior lines of therapy, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug.
The approval was based on findings from the phase 2 DREAMM-2 trial, which demonstrated an overall response rate of 31% in patients who received the recommended 2.5 mg/kg dose of belantamab mafodotin and 34% in patients who received the 3.4 mg/kg dose.